Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. - Wikidata - wikimedia - TriplyDB

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

http://www.wikidata.org/entity/Q36548370

about

Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options.Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review.Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.

P2860

Q33859061-AA099F6E-CB77-49EF-8CAA-D9B537DA4E81 Q33999284-738C3DEF-A169-4E2B-A5A4-0C6A3CB50A87 Q35750957-7CAEE6D0-8B6F-4548-A2E7-AE592458821D Q35850703-80401D84-B763-40B0-8853-8F80792E8D67 Q36557963-21DCF6F6-6AC8-44F1-A686-4ECA6FBA34E7 Q37061969-C23A38D3-7937-4459-8B2B-60CAAEAA5224 Q37159533-B4FDEE6F-956E-42B6-8471-5B62E337FA81 Q37842488-A6B57902-F625-43F0-93E1-96A5D0FEFD8E Q38104287-FE7E759A-43EA-4896-B83A-E9EC9A5E1F90 Q38119863-F9F55D48-68B2-4CBD-9CC3-656525A13BF9 Q40216218-D66A1C5E-E4DC-4BAF-A912-0D1847DA8160 Q43198291-D75C24FC-8F4F-42C1-8092-E7622667434A Q43616985-BDE7F696-2454-4977-A1B5-53100998060D

P2860

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

http://www.wikidata.org/entity/Q36548370

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@ast

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@en

type

label

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@ast

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@en

prefLabel

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@ast

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@en

P1433

Q36548370-C94F7B1A-82A5-4EA4-B46C-03199DDE5678

P1476

Q36548370-45928702-EF24-4FA0-9392-18C95EBE117A

P2093

Q36548370-754FCE98-5609-46F5-96E9-CB3CD80E5033

Q36548370-C25C15A8-E793-4362-B926-2806E66C7C46

P2860

Q36548370-0281BDCE-71E0-44AC-8302-0A0CC3371771

Q36548370-0E269A9B-EA26-4AF6-A2CA-DBC617A70C4C

Q36548370-0F46399B-97BC-4BC7-BF83-47602D2F3C8B

Q36548370-118A062D-C923-4805-8449-01A5E3B6DB4D

Q36548370-124F72CC-5CC5-4773-A911-10318D0D6A33

Q36548370-13AF9C39-6458-4F9E-85F8-CA66DF1BBD30

Q36548370-2A49BA38-D55E-4D8A-BB10-244EAA949632

Q36548370-2EC08657-82F7-45F7-A799-A3DDA32325B2

Q36548370-372396DE-EB34-4FCA-BA2E-AD9E622C0581

Q36548370-37ECA2A2-ED89-485C-BD62-DCDEEDD7A936

P2888

Q36548370-F57986D1-7911-4BD6-8DE0-0A589DCB7D8E

P304

Q36548370-101090E8-5F3F-4B7B-9AD9-143FDE9A8F06

P31

Q36548370-75951C7E-32E3-4FC7-80F8-F1FF7D8509BE

P356

Q36548370-3F74843D-69C9-4C99-B6DC-D363CD5DD86A

P433

Q36548370-2F14ACB9-E83B-4DBD-B80B-009966F853E9

P478

Q36548370-DD1377BF-ACA1-4E4D-AFA6-68E12032B608

P577

Q36548370-76E65F7E-96C8-409D-BF3A-FBE57B44655E

P5875

Q36548370-5E8B3D46-20DD-4381-9D66-803895209AFC

P698

Q36548370-CF06769E-B3DA-4544-A617-2DDC1F3D401E

P356

P1433

P1476

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

@en

P2093

Lazarus HM

http://www.w3.org/2001/XMLSchema#string

Rowe JM

http://www.w3.org/2001/XMLSchema#string

P2860

Palifermin for oral mucositis after intensive therapy for hematologic cancers

Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome.

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).

Nonmyeloablative allogeneic stem cell transplantation using alternative donors.

Graft-versus-host disease in mini-transplant.

Comorbidity indices in hematopoietic stem cell transplantation: a new report card.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

P2888

P304

1673-1682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404328

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6915691

http://www.w3.org/2001/XMLSchema#string

P698

16871280

http://www.w3.org/2001/XMLSchema#string